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Comparison of Surgery Plus Chemotherapy and 
Palliative Chemotherapy Alone for Advanced Gastric Cancer with
Krukenberg Tumor
Purpose
This study was conducted to validate the survival benefit of metastasectomy plus
chemotherapy over chemotherapy alone for treatment of Krukenberg tumors from gastric
cancer and to identify prognostic factors for survival.
Materials and Methods
Clinical data from 216 patients with Krukenberg tumors from gastric cancer were collected.
Patients were divided into two arms according to treatment modality: arm A, metastasec-
tomy plus chemotherapy and arm B, chemotherapy alone.
Results
Overall survival (OS) was significantly increased in arm A relative to arm B for patients initially
diagnosed with stage IV gastric cancer (18.0 months vs. 8.0 months; p < 0.001) and those
with recurrent Krukenberg tumors (19.0 months vs. 9.0 months; p=0.002), respectively.
Metastasectomy (hazard ratio [HR], 0.458; 95% confidence interval [CI], 0.287 to 0.732;
p=0.001), signet-ring cell pathology (HR, 1.583; 95% CI, 1.057 to 2.371; p=0.026), and
peritoneal carcinomatosis (HR, 3.081; 95% CI, 1.610 to 5.895; p=0.001) were significant
prognostic factors for survival.
Conclusion
Metastasectomy plus chemotherapy offers superior OS when compared to palliative
chemotherapy alone in gastric cancer with Krukenberg tumor. Prolonged survival applies
to all patients, regardless of gastric cancer stage. Metastasectomy, signet-ring cell pathology,
and peritoneal carcinomatosis were prognostic factors for survival. Future prospective 
randomized trials are needed to confirm the optimal treatment strategy for Krukenberg 
tumors from gastric cancer.
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Introduction
Gastric cancer is the second leading cause of cancer-related
death worldwide. In Western countries, the incidence of 
gastric cancer has been decreasing, whereas it remains a
main cause of cancer-related death in Korea. Gastric cancer
infrequently metastasizes to the ovary, a hormone-related
organ. The incidence of ovarian metastasis or Krukenberg
tumor after curative resection of gastric cancer is approxi-
mately 0.3%-6.7% [1,2]; however, some autopsy studies have
reported incidence rates ranging from 33% to 41% [1,2]. 
Krukenberg tumor is associated with poor prognosis in
gastric cancer [3,4]. In female patients, one of the most 
important causes of treatment failure for gastric cancer is an
ovarian relapse [5,6]. Significant advances have been made
in understanding the molecular biology of many cancers.
However, the underlying mechanism of the intratumor 
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heterogeneity of gastric cancer has not been clearly estab-
lished. Furthermore, the prognostic factors and treatment
guidelines for patients diagnosed with Krukenberg tumor of
gastric origin are insufficient.
Although systemic chemotherapy is the optimal treatment
strategy for recurrent or metastatic gastric cancer, it has not
provided significant survival benefits. Therefore, several
treatment strategies have been investigated to improve over-
all survival (OS) in metastatic gastric cancer patients with
oligometastases or limited metastasis. Several local treat-
ments including metastasectomy, radiofrequency ablation,
and stereotactic body radiation therapy have shown impres-
sive results [7,8]. Additionally, resection of metastatic lesions
has been shown to increase OS in colorectal cancer (CRC) 
patients with operable liver and lung metastases [9-12].
Therefore, National Comprehensive Cancer Network guide-
lines recommend metastasectomy for operable lung and liver
lesions in CRC. However, the survival benefit of metastasec-
tomy has not been clearly validated for Krukenberg tumors
in gastric cancer. Most Krukenberg tumors are diagnosed
metachronously, and only a few patients with Krukenberg
tumor are clinically diagnosed synchronously. In most 
hospitals, patients initially diagnosed with ovarian metasta-
sis in advanced gastric cancer are primarily treated with
chemotherapy. However, there is limited clinical data avail-
able regarding the survival benefit of ovarian metastasec-
tomy in patients with advanced gastric cancer [13]. More-
over, controversies regarding the best treatment strategy for
Krukenberg tumor in gastric cancer have caused confusion
among physicians. Therefore, we investigated the survival
benefit of ovarian metastasectomy in synchronous or metac-
hronous Krukenberg tumor in gastric cancer.
Materials and Methods
1. Patients
Of 27,103 patients who were diagnosed with gastric cancer
between March 2004 and February 2012 at Yonsei University
Medical Center, 9,217 (34%) were women. Among female
gastric cancer patients, 216 with Krukenberg tumor detected
by abdominal-pelvis computed tomography (CT) or gyneco-
logic ultrasonography were included in this study and 
reviewed retrospectively (Severance Hospital, n=172; Gang-
nam Severance Hospital, n=44). Patient information was 
obtained from outpatient clinical or admission records and
information regarding patient survival was obtained from
the Korean National Statistics Registry Database. The proto-
cols were approved by the Yonsei University Health System
Institutional Review Board. 
In general, curative surgery plays an important role in 
gastric cancer without distant metastasis. Therefore, for data
analysis, patients were divided into two groups according to
initial gastric cancer stage: stage I-III and stage IV. Patients
received surgery or palliative chemotherapy according to the
initial disease stage. Patients suspected of having Kruken-
berg tumor underwent imaging studies to confirm disease
resectability. However, 87% of patients (93/107) who under-
went oophorectomy had disease that already extended 
beyond the ovary, in which case oophorectomy was per-
formed for palliative symptom control. The residual disease
state of each patient was documented as the presence or 
absence of gross residual disease, which was classified as
negative resection margins (R0), microscopic tumor infiltra-
tion (R1), and macroscopic residual tumor (R2). R0 resection
was achieved in only 38% (41/107) of patients who under-
went oophorectomy.
Overall, 125 patients were initially diagnosed with stage
IV gastric cancer and 91 with recurrent Krukenberg tumor
after they underwent curative resection of gastric cancer.
Among the patients initially diagnosed with stage IV gastric
cancer, Krukenberg tumors were detected synchronously
and metachronously in 84 patients and 41 patients, respec-
tively.
To compare OS, patients with initial stage IV gastric cancer
(n=125) were divided into two arms according to treatment
modality. Arm A1 comprised 49 patients who received both
chemotherapy and metastasectomy for Krukenberg tumor.
Arm B1 comprised 76 patients who received chemotherapy
alone. Patients with recurrent Krukenberg tumor (n=91)
were assigned to arm A2 or arm B2. Arm A2 comprised 58
patients who received chemotherapy and metastasectomy
for recurrent Krukenberg tumor, and arm B2 comprised 33
patients who received chemotherapy alone. In arms A1 and
B1, OS was defined as the time from the date of pathologic
diagnosis of gastric cancer to the date of death or last follow-
up. In arms A2 and B2, OS was defined as the time from the
date of Krukenberg tumor diagnosis by imaging to the date
of death or last follow-up.
2. Statistical analyses
All statistical analyses were performed using IBM SPSS
ver. 20.0 (IBM Co., Armonk, NY). For continuous variables,
two-tailed Student t tests were used to compare the demo-
graphic and clinical characteristics between patient arms. For
discrete variables, a chi-square test was used. Survival rates
and 95% confidence intervals (CIs) were calculated using the
Kaplan-Meier method. The influence of the covariates on 
survival length between treatment arms was assessed using
the log-rank test. A p-value of < 0.05 was considered signif-
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icant. Significant variables in the univariate analysis were 
entered into multivariate analysis using the Cox proportional
hazards model.
Results
1. Clinical characteristics
The median follow-up duration for all patients was 30.0
months until the OS data cutoff date (June 30, 2013), at which
time 90% of the patients had discontinued treatment. The
Table 1. Clinical characteristics of 125 patients with initial stage IV gastric cancer
Variable Arm A1a) (n=49) Arm B1a) (n=76) p-valueb)
Median age (yr) 43.3 (26-69) 42.1 (27-72) 0.428
< 50 39 (80.0) 64 (84.2) 0.508
! 50 10 (20.4) 12 (15.8) -
Laterality 0.315
Bilateral 37 (75.5) 51 (67.0) -
Unilateral 12 (24.5) 25 (33.0) -
Krukenberg tumor size (cm) 7.99 (3.4-19) 5.76 (1.5-24) 0.004
Pathologic differentiation 0.236
WD-MD 7 (14.3) 6 ( 7.9) -
PD-SRC 42 (85.7) 69 (90.8) -
Chronology 0.676
Synchronous 34 (69.3) 50 (65.8) -
Metachronous 15 (30.6) 26 (34.2) -
Metastasis site
Peritoneum 38 (77.6) 66 (86.8) 0.175
Liver 6 (12.2) 10 (13.2) 0.881
Bone 5 (10.2) 11 (14.4) 0.723
Lung 2 (4.1) 5 (6.6) 0.704
Other 23 (46.9) 32 (42.1) 0.699
Extent of disease 0.028
Limited to the ovary 7 (14.3) 2 (2.6) - 
Beyond the ovary 42 (85.7) 74 (97.4) - 
R status
R0 resection 14 (28.6) - -
R2 resection 35 (71.4) - -
Serum CEA (ng/mL) 3.05 (0.01-36.3) 5.80 (0.01-121) 0.277
Normal 41 (83.7) 56 (73.7) 0.083
> 5 4 (8.2) 15 (19.7) -
Serum CA 19-9 (U/mL) 96.64 (0.1-1,850) 484.5 (0.1-12,100) 0.067
Normal 32 (65.3) 30 (39.5) 0.009
> 24 14 (28.6) 37 (48.7) -
Serum CA-125 (U/mL) 74.1 (5.5-244) 187 (11-1,555) 0.051
Normal 14 (28.6) 11 (14.5) 0.159
> 35 14 (28.6) 23 (30.3) -
Values are presented as median (range) or number (%). WD-MD, well differentiated adenocarcinoma and moderately differ-
entiated adenocarcinoma; PD-SRC, poorly differentiated adenocarcinoma and signet ring cell carcinoma; CEA, carcinoem-
bryonic antigen; CA, cancer antigen. a)Patients were divided into two arms according to treatment modality: arm A,
metastasectomy plus chemotherapy; arm B, chemotherapy alone, b)p-values from chi-square test except for Krukenberg tumor
size, and median age at Krukenberg tumor diagnosis, which were determined by a two-tailed Student t test.
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median age of patients at Krukenberg tumor diagnosis was
43.4 years (range, 21 to 78 years) and the average size of
metastatic ovarian tumors was 6.8 cm (range, 1.5 to 24 cm). 
The clinical characteristics of patients with initial stage IV
gastric cancer (n=125) are listed in Table 1. Patients were 
divided into two arms according to treatment modality: arm
A, metastasectomy plus chemotherapy; arm B, chemother-
apy alone. Comparison of the patients who received chem-
otherapy plus metastasectomy revealed they had signif-
icantly larger Krukenberg tumors (median size, 7.99 cm vs.
5.76 cm; p=0.004), fewer metastases outside the ovaries
(85.7% vs. 97.4%; p=0.028), and a more normal range of
Table 2. Clinical characteristics of 91 patients with recurrent Krukenberg tumor 
Variable Arm A2a) (n=58) Arm B2a) (n=33) p-valueb)
Median age (yr) 43.9 (21-78) 45.9 (25-75) 0.372
< 50 41 (70.7) 18 (54.5) 0.121
! 50 17 (29.3) 15 (45.5) -
Relapse free survival (mo) 24.3 (3-109) 27.8 (4-91) 0.435
Laterality 0.022
Bilateral 42 (72.4) 16 (48.5) -
Unilateral 16 (27.6) 17 (51.5) -
Krukenberg tumor size (cm) 7.39 (3-18) 5.95 (1.9-15) 0.068
Pathologic differentiation 0.499
WD-MD 6 (10.3) 5 (15.2) -
PD-SRC 52 (89.7) 28 (84.8) -
AJCC stage 0.824
I, II 26 (44.8) 14 (42.4) -
III 32 (55.2) 19 (57.6) -
Metastasis site
Peritoneum 45 (77.6) 26 (78.8) 0.894
Liver 4 (6.9) 4 (12.1) 0.454
Bone 6 (10.3) 5 (15.2) 0.519
Lung 2 (3.4) 0 (0) 0.533
Other 33 (56.9) 13 (39.4) 0.108
Extent of disease 0.250
Limited to the ovary 7 (12.1) 1 (3.0) -
Beyond the ovary 51 (87.9) 32 (97.0) -
R status
R0 resection 27 (46.6) - -
R2 resection 31 (53.4) - -
Serum CEA (ng/mL) 2.79 (0.13-22.2) 332 (0.65-10,410) 0.319
Normal 44 (75.9) 24 (72.7) 0.276
> 5 8 (13.8) 8 (24.2) -
Serum CA 19-9 (U/mL) 118.73 (0.1-2,270) 1,702 (0.1-20,000) 0.097
Normal 38 (65.6) 15 (45.5) 0.035
> 24 14 (25.0) 15 (45.5) -
Serum CA-125 (U/mL) 36.4 (4-241) 60.82 (5-227.8) 0.117
Normal 33 (56.9) 10 (30.3) 0.080
> 35 11 (19.0) 9 (27.3) -
Values are presented as median (range) or number (%). WD-MD, well differentiated adenocarcinoma and moderately differ-
entiated adenocarcinoma; PD-SRC, poorly differentiated adenocarcinoma and signet ring cell carcinoma; AJCC, American
Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA, cancer antigen. a)Patients were divided into two arms 
according to treatment modality: arm A, metastasectomy plus chemotherapy; arm B, chemotherapy alone, b)p-values from
chi-square test except for Krukenberg tumor size, median age at Krukenberg tumor diagnosis, and relapse free survival, which
were determined by a two-tailed Student t test.
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serum cancer antigen (CA) 19-9 level (65.3% vs. 39.5%;
p=0.009) than patients who received chemotherapy alone.
The clinical characteristics of patients with recurrent
Krukenberg tumor of gastric origin (n=91) are listed in Table
2. Patients who received chemotherapy plus metastasectomy
had significantly higher frequency of bilateral tumors (72.4%
vs. 48.5%; p=0.022), and a more normal range of serum CA
19-9 level (65.6% vs. 45.5%; p=0.035) than those who received
chemotherapy alone.
2. Treatment outcome
The median OS of patients with initial stage IV gastric 
cancer was 12.0 months (95% CI, 9.7 to 14.3 months). The 
median OS of arm A1 and arm B1 was 18.0 months (95% CI,
15.2 to 20.8 months) and 8.0 months (95% CI, 6.6 to 9.4
months), respectively. Therefore, patients in the chemother-
apy plus metastasectomy arm had a significantly better OS
than patients in the chemotherapy arm (p < 0.001) (Fig. 1). 
The median OS of patients with recurrent Krukenberg 
tumors was 15.0 months (95% CI, 12.7 to 17.3 months). The
median OS time of arm A2 and arm B2 was 19.0 months (95%
CI, 14.4 to 23.6 months) and 9.0 months (95% CI, 6.2 to 11.8
months), respectively. Patients in the chemotherapy plus
metastasectomy arm had a significantly better OS than 
patients in the chemotherapy alone arm (p=0.002) (Fig. 2). 
Upon univariate analysis of all patients, metastasectomy,
signet-ring cell pathology, presence of peritoneal carcino-
matosis, gastrectomy, and elevated serum levels of carci-
noembryonic antigen (CEA; > 5 ng/mL), CA 19-9 (> 24
U/mL), and CA-125 (> 35 U/mL) were prognostic factors 
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Fig. 3. Kaplan-Meier overall survival based on curative 
resection of Krukenberg tumor in stomach cancer. The
residual disease state of each patient was documented as
the presence or absence of gross residual disease, which
was classified as negative resection margins (R0), micro-
scopic tumor infiltration (R1), and macroscopic residual
tumor (R2).
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Fig. 2. Kaplan-Meier overall survival based on treatment
arm with recurred Krukenberg tumor. Patients were 
divided into two arms according to treatment modality:
arm A, metastasectomy plus chemotherapy; arm B,
chemotherapy alone.
Fig. 1. Kaplan-Meier overall survival based on treatment
arm in initial stage IV gastric cancer. Patients were 
divided into two arms according to treatment modality:
arm A, metastasectomy plus chemotherapy; arm B,
chemotherapy alone.
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associated with survival. After adjusting for covariates in
multivariate analysis, metastasectomy (hazard ratio [HR],
0.458; 95% CI, 0.287 to 0.732; p=0.001), signet-ring cell pathol-
ogy (HR, 1.583; 95% CI, 1.057 to 2.371; p=0.026), and presence
of peritoneal carcinomatosis (HR, 3.081; 95% CI, 1.610 to
5.895; p=0.001) were independent predictors of OS (Table 3). 
It was difficult to statistically analyze survival differences
between patients in whom metastasis was limited to the
ovary and those who have metastasis beyond the ovary 
because only 8% of patients showed metastasis limited to the
ovary. Most of these patients were alive at the time of the
study. A few patients who showed metastasis to other sites
were subjected to additional surgery with oophorectomy,
such as total hysterectomy and bowel resection.
As shown in Fig. 3, the R0 resection group (n=41) had a
significantly longer OS (HR, 0.405; 95% CI, 0.254 to 0.646; 
log-rank p < 0.001) than the R1, R2 resection group (n=66).
The median OS was 30.0 months (95% CI, 24.0 to 36.0) in the
R0 resection group and 15.0 months (95% CI, 13.6 to 16.4) in
the R1, R2 resection group. 
Oophorectomy was found to still be beneficial when other
unresectable metastasis were present, for both metastatic and
recurrent disease. Analysis of all cases except single ovarian
metastasis revealed that the median OS time of arm A1 and
arm B1 was 16.0 months (95% CI, 13.7 to 18.3 months) and
8.0 months (95% CI, 6.6 to 9.4 months; p < 0.001), respec-
tively. Additionally, the median OS time of arm A2 and arm
B2 was 16.0 months (95% CI, 12.5 to 19.5 months) and 8.0
months (95% CI, 5.8 to 10.2 months; p=0.039), respectively.
The frequencies and response rates of chemotherapy regi-
Table 3. Univariate and multivariate analysis showing factors associated with overall survival in 216 patients 
Variable Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Metastasectomy 0.404 (0.302-0.539) < 0.001 0.458 (0.287-0.732) 0.001
Age (! 50 yr) 1.065 (0.769-1.477) 0.704 - -
Metachronous disease 0.870 (0.587-1.289) 0.487 - -
Unilateral ovarian metastases 1.097 (0.809-1.487) 0.552 - -
Size of Krukenberg tumor (< 5 cm) 0.749 (0.547-1.024) 0.070 - -
Signet-ring cells 0.642 (0.479-0.859) 0.003 1.583 (1.057-2.371) 0.026
Peritoneal carcinomatosis 3.034 (1.990-4.625) < 0.001 3.081 (1.610-5.895) 0.001
Gastrectomy 2.022 (1.507-2.712) < 0.001 1.293 (0.787-2.124) 0.311
Relapse free survival (! 12 mo) 1.433 (0.958-2.144) 0.080 - -
CEA 1.434 (1.061-1.938) 0.052 - -
CA 19-9 1.614 (1.193-2.182) 0.002 0.683 (0.447-1.042) 0.077
CA-125 2.091 (1.420-3.078) < 0.001 0.653 (0.421-1.014) 0.057
HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; CA, cancer antigen.
Table 4. Frequencies and response rates of chemotherapy regimens initially used after ovarian metastasis diagnosis 
Variable Arm A1
a) Arm A2 Arm B1 Arm B2 Total
No. RR (%)b) No. RR (%) No. RR (%) No. RR (%) No. RR (%)
Platinumc) 8 25 1 0 21 14 13 46 43 26
Irinotecand) 0 0 0 0 4 25 4 25 8 25
Taxanee) 4 0 2 0 17 18 3 0 26 12
Total 12 17 3 0 42 17 20 35 77 21
a)Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus chemotherapy; arm B,
chemotherapy alone, b)RR, response rate (comlete response or partial response patients/total patients), c)Cisplatin+TS-1, 
cisplatin+capecitabine (XP), cisplatin+5-fluorouracil (5-FU) (FP), oxaliplatin+capecitabine (XELOX), oxaliplatin+5-FU/
leucovorin (LV) (FOLFOX), oxaliplatin+TS-1 (SOX), d)Irinotecan mono, irinotecan+TS-1, irinotecan+5-FU/LV (FOLFIRI), 
e)Paclitaxel mono, paclitaxel+5-FU/LV, paclitaxel+TS-1, docetaxel mono, docetaxel+5-FU/LV, docetaxel+TS-1,
docetaxel+capecitabine. 
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mens initially used after ovarian metastasis diagnosis were
also analyzed (Table 4). Overall, 111 patients were treated
with chemotherapy for ovarian metastasis, with platinum
(n=43), taxane (n=26), and irinotecan (n=8) chemotherapy
regimens being the most frequently used. Chemotherapy
regimens did not differ significantly between arms A and B
(p=0.535). Patients who received chemotherapy for ovarian
metastasis were evaluated using the Response Evaluation
Criteria in Solid Tumors ver. 1.1. Tumor assessment included
measurable metastatic ovarian lesions and not overall gastric
cancer lesions. The response rates for the chemotherapy 
regimens were as follows: platinum, 26%; irinotecan, 25%;
and taxane, 12%.
Discussion
Most patients diagnosed with Krukenberg tumor of gastric
origin have poor prognosis. Many studies have shown that
the median survival after Krukenberg tumor diagnosis is 
7-11 months [13]. In the past, symptomatic patients received
palliative operation for symptom relief. Recently, the devel-
opment of diagnostic tools has increased early detection of
Krukenberg tumors and their curative resectability. Never-
theless, the optimal treatment strategy for Krukenberg 
tumors has not been established.
Our study showed that patients with Krukenberg tumor
of gastric origin who underwent both chemotherapy plus
metastasectomy had longer OS than those who underwent
chemotherapy alone, regardless of stage. The difference in
OS was actually underestimated because the OS in arms A2
and B2 was determined from the date of recurrent Kruken-
berg tumor diagnosis and not the date of the initial gastric
cancer diagnosis. Despite the small proportion of R0 resec-
tions, a prolonged OS was observed in the chemotherapy
plus metastasectomy arm. In our study, one patient in arm
A1 survived more than 9 years after the initial diagnosis of
gastric cancer, while one patient in arm A2 survived more
than 7.5 years after resection of metachronous Krukenberg
tumor. 
Some studies have reported the survival benefit of metas-
tasectomy for Krukenberg tumor; however, most of these 
included a small number of patients (approximately 50 
patients) and Krukenberg tumors of different origins, includ-
ing gastric, colon, and breast cancers [14]. Many reports have
suggested that metastasectomy provides a better survival
benefit for Krukenberg tumors of CRC origin [15-17]. Among
studies of the survival benefit of metastasectomy for Kruken-
berg tumor, ours is the largest conducted to date and the only
one that investigated Krukenberg tumors of gastric cancer
origin exclusively. A few studies have demonstrated that
metastasectomy of metachronous recurrent Krukenberg
tumor of gastric origin provided longer OS [18-20]. Based on
our results, metastasectomy should be performed in stage 
IV gastric cancer patients diagnosed synchronously or
metachronously with Krukenberg tumor. Our recommenda-
tion is consistent with those of previous reports [21,22].
In the present study, the prognostic factors associated with
survival in patients with Krukenberg tumor of gastric origin
were analyzed. Metastasectomy, signet-ring cell pathology,
and peritoneal carcinomatosis were identified as significant
prognostic factors. Several studies have also shown that
metastasectomy is a prognostic factor for better OS in 
patients with Krukenberg tumors [18,19]. In the present
study, absence of peritoneal carcinomatosis was associated
with better prognosis, which is consistent with the results of
a previous study that showed limited disease extent as a
prognostic factor [2]. Complete resection is easily achieved
when the extent of disease is limited; therefore, active
Krukenberg tumor metastasectomy should be conducted in
patients who are not expected to have residual disease after
operation. Adenocarcinomas composed of signet ring cells
tend to metastasize to the ovaries more frequently than 
adenocarcinomas of other histologic types [23]. Signet ring
cell features have not been well established as a prognostic
factor for Krukenberg tumors; however, in the present study,
they were a poor prognostic factor for Krukenberg tumors
of gastric cancer origin.
Published studies of the role of chemotherapy in the treat-
ment of Krukenberg tumors have included only small patient
numbers or case reports. In the present study, response rates
to chemotherapy regimens were analyzed in 111 patients 
diagnosed with Krukenberg tumor, and response rates
ranged from 12% to 26%. In most of our cases, Krukenberg
tumor was diagnosed during later stages of gastric cancer
progression. Therefore, at the time of Krukenberg tumor 
diagnosis, patients have already received standard first-line
chemotherapy for advanced or metastatic gastric cancer.
In our experience, ovarian metastases show less chem-
otherapy responsiveness than other sites of metastasis. Early
detection of ovarian metastases is important to successful
treatment. In the present study, serum CEA, CA 19-9, and
CA-125 level were not useful predictors of Krukenberg
tumor. Despite continual efforts to develop a practical 
biomarker that can predict relapse or metastasis of ovary
metastasis with gastric cancer, no clinical tests have been 
established [24].
Clinical heterogeneity is most likely due to the diverse 
molecular profile of gastric cancer. Thus, identifying diver-
sity in the molecular profile of gastric cancer that governs the
clinical behavior of tumors could lead to new and more 
effective clinical strategies. Recent studies of gastric cancer
Cancer Res Treat. 2015;47(4):697-705
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have identified genes that differ according to histologic 
factors and age, as well as those useful for gastric cancer
prognosis prediction [24]. We will continue to identify genes
and develop a practical biomarker in future studies.
It should be noted that several factors may have affected
the decision of surgery for treatment of the patients evalu-
ated in the present study, including the extent of metastasis,
possibility of curative surgery, surgeon’s opinion, etc. Addi-
tionally, the difference in the chemotherapy regimen 
between arm A and arm B may have influenced patient 
survival or toxicity.
CT was used to identify patients who would benefit from
the curative resection of Krukenberg tumors. Although 
imaging modalities, including CT scanning, have been 
developed to detect intraperitoneal metastasis, CT has been
shown to only have a 50% accuracy for detecting intraperi-
toneal metastatic cancers [25]. Therefore, peritoneal carcino-
matosis is difficult to diagnosis by CT scan. Laparoscopic 
examination has shown better accuracy in detecting peri-
toneal carcinomatosis; however, this procedure is invasive
and can result in complications.
Conclusion
In conclusion, we demonstrated that metastasectomy was
associated with longer survival in patients with Krukenberg
tumors in gastric cancer. Therefore, metastasectomy should
be performed in stage IV gastric cancer patients diagnosed
synchronously or metachronously with Krukenberg tumor.
Our data also suggest that metastasectomy plus chemother-
apy may play a role in the treatment of Krukenberg tumors
of gastric origin. Furthermore, we found that metastasec-
tomy, signet ring cells, and peritoneal carcinomatosis were
prognostic factors for Krukenberg tumors. Future prospec-
tive randomized trials are needed to confirm our findings
and will be important in establishing standard treatment
guidelines for patients with Krukenberg tumor in metastatic
gastric cancer.
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